Risk.net

Losses & Lawsuits

LOSS DATABASE

  • LinkedIn  
  • Save this article
  • Print this page  

Durus Capital Management

The US Securities and Exchange Commission filed on October 12 fraud charges against hedge fund Durus Capital Management, and its principals, Scott Sacane and J Douglas Schmidt. The SEC complaint charges Sacane and Schmidt with instigating fraudulent schemes during 2002 and 2003 involving the common stock of two biotechnology companies: Esperion Therapeutics and Aksys. Schmidt has since pleaded guilty to filing false statements.

Once the alleged frauds were disclosed in

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Copyright Infopro Digital Limited. All rights reserved.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

Copyright Infopro Digital Limited. All rights reserved.

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

If you already have an account, please sign in here.

More on People

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here